阿托伐他汀钙片致全身严重皮疹1例分析

doi:10.19803/j.1672-8629.20240094

摘要/Abstract

摘要： 目的分析阿托伐他汀引起全身严重皮疹的临床特点及可能致敏机制,为慢病患者多重用药提供警示,并为其早期临床处置提供参考。方法通过1例老年脑梗死患者多重用药（氨氯地平、阿司匹林、阿托伐他汀、尤瑞克林、依达拉奉右崁醇）后出现全身皮疹,停用尤瑞克林、依达拉奉右崁醇,调整阿司匹林为氯吡格雷后患者皮疹仍加重,停用全部药物（只保留抗过敏药物）后皮疹逐渐消退,后恢复氯吡格雷、氨氯地平后患者皮疹未复发的全病程,采用Naranjo评分及结合文献资料,分析可能致敏的药物。结果根据患者皮疹的临床表现以及皮疹消退的时间与临床用药的关系,结合阿托伐他汀Naranjo评分5分,考虑其很有可能是引起患者皮疹的药物。结论慢病患者多重用药过程中,临床需注意阿托伐他汀钙片可在用药数天后引起全身严重皮疹。

关键词: 阿托伐他汀钙片, 严重皮疹, 脑梗死, 不良反应, 多重用药, 慢病管理

Abstract: Objective To analyze the clinical characteristics and potential allergenic mechanisms of atorvastatin induced severe generalized rash in patients with chronic diseases, providing a warning for future polypharmacy and reference for early clinical management. Methods A retrospective study was conducted on a patient with cerebral infarction who developed a generalized rash after polypharmacy (amlodipine, aspirin, atorvastatin, urinary kallidinogenase and edaravone dexborneol) was conducted. The rash worsened even after discontinuing urinary kallidinogenase and edaravone dexborneol and switching aspirin to clopidogrel. The rash subsided only after discontinuing all medications except for antiallergic drugs. When clopidogrel and amlodipine were reintroduced, the rash did not recur. The Naranjo score and literature review were used to analyze the potential allergenic drug. Results Based on the clinical presentation of the rash and its relationship with the timing of medication, combined with the Naranjo score of 5 for atorvastatin, it is very likely that atorvastatin is the drug causing the patient’s rash. Conclusions Clinicians should be aware that atorvastatin can cause severe generalized rash in chronic diseases patients a few days after administration during polypharmacy.

Key words: atorvastatin calcium, severe rash, cerebral infarction, adverse reaction, multiple drug, chronic disease management

中图分类号:

R972
R994.11

李芳, 龙秀英, 柏娜, 魏京霞. 阿托伐他汀钙片致全身严重皮疹1例分析[J]. 中国药物警戒, 2024, 21(8): 939-942.

LI Fang, LONG Xiuying, BAI Na, WEI Jingxia. One case of severe systemic rash caused by atorvastatin calcium tablets[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 939-942.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240094

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I8/939

参考文献

[1] ZHAO Y, ATUN R, OLDENBURG B, et al.Physical multimorbidity, health service use, and catastrophic health expenditure bysocioeconomic groups in China: an analysis of population-based panel data[J]. Lancet Glob Health, 2020, 8(6): e840-e849.
[2] National Key Research and Development Project research Group (2018YFC2002400). Expert consensus on the safety management of multiple medications for elderly comorbidities patients[J]. Chinese Journal of Health Care and Medicine(中华保健医学杂志), 2021, 23(5): 548-554.
[3] JIANG J, ZHANG YF, WANG JL, et al.Investigation and analysis of the complexity and suitability of drug treatment plans for elderly hospitalized patients[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2021, 30(3): 196-200.
[4] HANSON K, MATTES RG, CAUTHON KAB.Drug eruption from atorvastatin: with initial misdiagnosis of tinea cruris[J]. Sr Care Pharm, 2023, 38(2): 63-69.
[5] GRESSIER L, PRUVOST-BALLAND C, DUBERTRET L, et al.Syndrome d’hypersensibilité médicamenteuse induit par l’atorvastatine [Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS)][J]. Ann Dermatol Venereol, 2009, 136(1): 50-53.
[6] CAO X, LI YJ, SONG YQ, et al.Allergic reactions Induced by Statins[J]. Evaluation and analysis of drug use in hospitals of China, 2022, 22(1): 125-128.
[7] LI YY. 5 Cases of adverse reactions caused by injection of urinary kallidinogenase[J]. Chinese Journal of Pharmacovigilance (中国药物警戒), 2008, 5(5): 317, 319.
[8] XU J, WANG A, MENG X, et al.Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase iii, randomized, double-blind, comparative trial[J]. Stroke, 2021, 52(3): 772-780.
[9] WANG W, CEHN XL, WU SF.Analysis of 4760 ADR reports of aspirin enteric-coated tablets[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(6): 354-356.
[10] Chinese Medical Association, Journal of the Chinese Medical Association, Dermatology and Venereology Branch of the Chinese Medical Association, General Practitioner Branch of the Chinese Medical Association, Editorial Committee of the Chinese Journal of General Practitioners of the Chinese Medical Association, and Expert Group for Writing Grassroots Diagnosis and Treatment Guidelines for Dermatology and Venereology. Guidelines for grassroots diagnosis and treatment of drug rash[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2022, 21(9): 804-813.
[11] Prevention of Food and Drug Allergy Group of the Allergic Disease Prevention and Control Professional Committee of the Chinese Association of Preventive Medicine. Expert consensus on Drug Stimulation Trials[J]. Chinese Journal of Preventive Medicine(中华预防医学杂志), 2020, 54(10): 1060-1068.
[12] MURAYAMA H, SAKUMA M, TAKAHASHI Y, et al.Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: the Japan adverse drug events study[J]. Pharmacology Research & Perspectives, 2018, 6(1): e00373.
[13] MURALI M, SUPPES SL, FELDMAN K, et al.Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children’s hospital[J]. PloS one, 2021, 16(1): e0245368.
[14] NAMAZI MR.Statins: novel additions to the dermatologic arsenal?[J]. Exp Dermatol,2004, 13(6): 337-339.
[15] LV M, JIANG S, FU J, et al.Toxic epidermal necrolysis in a patient on atorvastatin therapy expressing human leukocyte antigen alleles: a case report[J]. Medicine (Baltimore), 2021, 100(3): e24392.
[16] COZZANI E, SCAPARRO M, PARODI A.A case of psoriasis worsened by atorvastatin[J]. J Dermatol Case Rep, 2009, 3(4): 60-61.
[17] HUERTAS AJ, RAMIREZ-HERNANDEZ M, MERIDA-FERNANDEZ C, et al.Fixed drug eruption due to atorvastatin[J]. J Investig Allergol Clin Immunol, 2015, 25(2):155-156
[18] ZHU YM, CAO JG, ZHOU YS.Application of gene detection in individualized treatment of lipid -lowering drugs[J]. China Pharmacy(中国药房), 2023, 34(9): 1147-1152.